- ADC Therapeutics ( NYSE: ADCT ) said the first patient was dosed in a phase 1b trial of Zynlonta in combination with other anti-cancer agents in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
- Zynlonta (loncastuximab tesirine-lpyl) is approved in the U.S. to treat adult patients with relapsed or refractory large B-cell lymphoma who have received two or more lines of systemic therapy, the company noted.
- ADC said the first group of the study, dubbed LOTIS-7, will evaluate Zynlonta in combination with Roche's Polivy (polatuzumab vedotin) to treat patients with relapsed or refractory B-cell non-Hodgkin lymphoma, including diffuse large B-cell, high grade B-cell, follicular, mantle cell, marginal zone and Burkitt lymphomas.
- B-cell NHL develops when the body makes abnormal B lymphocytes, a type of white blood cells.
For further details see:
ADC Therapeutics begins dosing in study of Zynlonta combo for blood cancer subtype